<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trials
Susan D. Richman(University of Leeds), Philip Quirke(University of Leeds), Joseph Foster(University of Miami), Philip Chambers(University of Leeds), Henry M. Wood(University of Leeds), Karen G. Spink(Pfizer (United Kingdom)), Katie Southward(University of Leeds), David Kerr(University of Oxford), Morag Taylor(University of Leeds), Gordon Hutchins(Leeds General Infirmary), Michel Seymour(University of Leeds), Jennifer H. Barrett(University of Leeds), Kelly Handley, Sarah Brown(University of Leeds), Richard Gray(Barnsley Hospital NHS Foundation Trust), Marc Jones(University of Leeds), Gemma Hemmings(University of Leeds), Debra Cross(St James's University Hospital), Assa Oumie
Cited by 238
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
International network of cancer genome projects
|Nature|2010|2.4k
The Proteomics Identifications (PRIDE) database and associated tools: status in 2013
|Nucleic Acids Research|2012|2k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k